05:20 PM EDT, 10/03/2025 (MT Newswires) -- Kevin Joseph Fitzgerald, Chief Scientific Officer & Executive Vice President, Head of Research, on October 01, 2025, sold 2,441 shares in Alnylam Pharmaceuticals ( ALNY ) for $1,103,451. Following the Form 4 filing with the SEC, Fitzgerald has control over a total of 25,768 common shares of the company, with 25,231 shares held directly and 537 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/1178670/000173527625000114/xslF345X05/edgardoc.xml